Applied Molecular Transport Gets New FDA Orphan Drug Designation
11 November 2022 - 01:10AM
Dow Jones News
By Sabela Ojea
Applied Molecular Transport Inc. said Thursday that the U.S.
Food and Drug Administration has granted Orphan Drug Designation
for its AMT-101 drug, aimed at the treatment of inflammation
pouchitis.
The biopharmaceutcial company said there are currently no
FDA-approved products to treat pouchitis, a severe end-stage
complication of ulcerative colitis.
The FDA's Orphan Drug Designation is granted to drugs intended
to treat a rare disease or condition in the U.S.
At premarket trading, shares of Applied Molecular Transport were
up 2.2% at 95 cents.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 10, 2022 08:55 ET (13:55 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Mar 2023 to Apr 2023
Applied Molecular Transp... (NASDAQ:AMTI)
Historical Stock Chart
From Apr 2022 to Apr 2023
